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Abstract 
Background: People living in malaria endemic areas acquire protection from severe malaria quickly, but protection 
from clinical disease and control of parasitaemia is acquired only after many years of repeated infections. Antibodies 
play a central role in protection from clinical disease; however, protective antibodies are slow to develop. This study 
sought to investigate the influence of Plasmodium falciparum exposure on the acquisition of high‑avidity antibodies 
to P. falciparum antigens, which may be associated with protection.
Methods: Cross‑sectional surveys were performed in children and adults at three sites in Uganda with varied P. falci-
parum transmission intensity (entomological inoculation rates; 3.8, 26.6, and 125 infectious bites per person per year). 
Sandwich ELISA was used to measure antibody responses to two P. falciparum merozoite surface antigens: merozoite 
surface protein 1‑19 (MSP1‑19) and apical membrane antigen 1 (AMA1). In individuals with detectable antibody levels, 
guanidine hydrochloride (GuHCl) was added to measure the relative avidity of antibody responses by ELISA.
Results: Within a site, there were no significant differences in median antibody levels between the three age groups. 
Between sites, median antibody levels were generally higher in the higher transmission sites, with differences more 
apparent for AMA‑1 and in ≥5 year group. Similarly, median avidity index (proportion of high avidity antibodies) 
showed no significant increase with increasing age but was significantly lower at sites of higher transmission amongst 
participants ≥5 years of age. Using 5 M GuHCl, the median avidity indices in the ≥5 year group at the highest and 
lowest transmission sites were 19.9 and 26.8, respectively (p = 0.0002) for MSP1‑19 and 12.2 and 17.2 (p = 0.0007) for 
AMA1.
Conclusion: Avidity to two different P. falciparum antigens was lower in areas of high transmission intensity com‑
pared to areas with lower transmission. Appreciation of the mechanisms behind these findings as well as their clinical 
consequences will require additional investigation, ideally utilizing longitudinal data and investigation of a broader 
array of responses.
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Background
Malaria caused by Plasmodium falciparum is a major 
global public health challenge, accounting for an esti-
mated 214 million clinical cases and 438,000 deaths in 
2015 [1]. People living in endemic areas acquire pro-
tection from the most severe manifestations of malaria 
relatively quickly, but protection from uncomplicated 
clinical disease and control of parasitaemia takes longer 
and is often acquired only after many years of repeated 
infections [2]. Moreover, sterile immunity to P. falci-
parum is rarely if ever achieved. Passive transfer of 
immunoglobulin from clinically immune donors to 
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non-immune individuals with P. falciparum infection 
alleviated clinical symptoms and reduced the levels of 
blood stage parasites, indicating that antibodies play a 
central role in clinical immunity to malaria [3, 4]. How-
ever, numerous studies have measured antibody levels 
to various P. falciparum antigens with conflicting results 
regarding correlates of protection [5–10]. The quali-
ties of protective antibodies and precise mechanisms by 
which they mediate protection are not fully understood.
Antibody properties including breadth of response, 
isotype composition, and avidity appear to play an 
important role in protective immunity [11–13]. Anti-
body avidity reflects the overall strength of interaction 
between the antibody and antigen complex and corre-
lates with protection in naturally acquired and vaccine 
induced immunity to viral and bacterial pathogens [14–
17]. In P. falciparum infection, avidity to whole schiz-
ont extract, as well as to a number of specific antigens, 
has been shown to correlate with protection [18–21]. 
However, acquisition of high antibody avidity to P. fal-
ciparum antigens with increasing age and varied P. fal-
ciparum exposure intensity is poorly understood.
In general, repeated exposure to an antigen results in 
germinal centre reactions which lead to affinity matura-
tion and increases in antibody avidity [22–24]. However, 
there is also evidence to suggest that P. falciparum infec-
tion directly interferes with B cell function [2, 8, 25] and 
disrupts germinal centre architecture [26, 27], potentially 
interfering with affinity maturation [ [26, 27]. One study 
performed in a setting of unstable malaria transmission 
showed evidence of increased antibody avidity following 
resolution of a clinical malaria episode [18]. In contrast, 
two studies of children living in endemic areas failed to 
observe an increase in avidity to a number of P. falcipa-
rum antigens with increasing exposure [28, 29]. Overall, 
it is unclear if repeated exposure to P. falciparum leads to 
increased avidity of antibodies directed against plasmo-
dium antigens.
To determine the influence of P. falciparum expo-
sure on the natural acquisition of high-antibody avidity, 
avidity indices to two P. falciparum merozoite surface 
antigens were measured in individuals across a wide 
range of ages from cross-sectional surveys performed 
in three sites in Uganda with varying transmission 
intensity. Antibody avidity indices were then compared 
between ages and sites to determine whether there 
were differences in antibody avidity associated with age 
and P. falciparum exposure intensity.
Methods
Study sites and cross‑sectional surveys
This study took place in three sub-counties in Uganda 
with varied P. falciparum transmission intensity. 
Walukuba, a peri-urban area near Lake Victoria, had 
relatively low transmission intensity, with an entomologi-
cal inoculation rate (EIR) estimated at 3.8 infectious bites 
per person per year (IBPPY) [30]. Kihihi, a rural area in 
the south-western part of Uganda, had higher transmis-
sion, with an estimated EIR of 26.6 IBPPY. Nagongera, a 
rural area in the south-eastern part of the country, had 
the highest transmission, with an estimated EIR of 125 
IBPPY. Malaria transmission at all three sites was per-
ennial. Malaria control interventions in all three dis-
tricts included use of long lasting insecticide treated nets 
(LLIN), malaria case management with artemisinin based 
therapies, and intermittent presumptive treatment dur-
ing pregnancy with sulfadoxine–pyrimethamine.
Cross-sectional surveys were conducted between Jan-
uary and June 2012 at all three sites [31]. Survey staff 
recruited members from 200 households randomly 
selected from a population-based census. Dried blood 
spots (DBS) from finger-prick samples were obtained 
from all children under 15 years of age and from a ran-
dom selection of age stratified adults in the following 
categories: 15–24, 25–34, 35–44, 45–54, and >55  years. 
The cross-sectional survey resulted in recruitment of 
2737 participants of which 2227 had ELISA results. For 
this study, 581 and 1029 participants who had reactive 
antibodies with normalized OD >0.5 were analysed for 
avidity to MSP-1 and AMA-1 respectively. This allowed 
inclusion of participants who might have had a more 
recent antibody boost for a more direct comparison 
across sites.
Ethical approval and informed consent
Ethical approval was obtained from the Makerere Uni-
versity School of Medicine Research and Ethics Com-
mittee (REC REF 2011–203), Uganda National Council 
for Science and Technology (HS 1074), London School 
of Hygiene & Tropical Medicine Ethics Committee 
(Reference 6012), and the University of California, 
San Francisco Committee on Human Research (Refer-
ence 027911). Written informed consent was obtained 
from the parents/guardians on behalf of the children 
enrolled in the study and from all participants above 
18 years of age. Assent was obtained from all children 
8–17 years.
Elution of antibodies from dried blood spots (DBS)
DBS were collected on Whatman 3MM filter paper and 
stored at −20 °C. For this study, a 3 mm diameter punch 
of DBS was hydrated in 200  µl of phosphate buffered 
saline (PBS) containing 0.005% Tween 20 and 0.01% 
sodium azide. The samples were left on a plate shaker 
overnight at room temperature before storage at 4  °C. 
The excised spot was estimated to contain approximately 
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2 µl plasma, resulting in a serum dilution factor of 1:200 
[32].
Modified ELISA to measure the avidity index
Antibodies to MSP1-19 (Wellcome strain) [33] and 
AMA-1 (FVO strain) [34] were measured via a stand-
ard sandwich ELISA method [28, 31]. In brief, Immu-
lon-4 HBX microtitre plates (Thermo Labsystems, 
Basingstoke, UK) were coated overnight at 4  °C with 
0.5  mg/ml of antigen in coating buffer (0.1  M sodium 
carbonate/bicarbonate, pH 9.6), and then washed three 
times with wash buffer; PBS, 0.05% Tween-20. Plates 
were blocked for 3 h at room temperature with 200 µl/
well PBS, 0.05% Tween-20, 1% skimmed dried milk and 
then washed three times. For each sample, plasma was 
diluted to a final concentration of 1:1000 for MSP1-
19 and 1:2000 for AMA1, with 50 μl of diluted plasma 
added per well. Plates were incubated overnight at 
4  °C and washed six times. HRP-conjugated rabbit 
anti-human IgG (Dako Ltd, High Wycombe, UK) was 
diluted 1:5000 in blocking buffer and 50  μl was added 
per well. Plates were incubated for 3  h at room tem-
perature, then washed six times and developed with 
100  µl/well of o-phenylenediamine (OPD)–H2O2. 
The reaction was stopped after 15 min with 25 μl 2 M 
sulphuric acid. ODs were measured at 492  nm using 
a VERSAmax plate reader, with Softmax software 
(Molecular Devices, USA).
To evaluate antibody avidity, the sandwich ELISA assay 
described above was modified to include an antibody 
disassociation step prior to addition of HRP-conjugated 
secondary antibody [29, 35, 36]. Briefly, diluted plasma 
samples were incubated on the plates overnight at 4  °C, 
antibody avidity was measured by treating duplicate 
wells with 2 or 5  M guanidine hydrochloride (GuHCl) 
for 10  min and then washing six times. PBS was used 
for the control wells to measure the total antibody bind-
ing. Test samples with and without GuHCl were run on 
the same plate to minimize variability. The avidity index 
(AI) was defined as the proportion of antibodies bind-
ing after treatment with GuHCl for each dilution (Avid-
ity index = [OD following GuHCl treatment/OD without 
GuHCl treatment] × 100).
In order to overcome the limitations of avidity meas-
urement by ELISA (poor resolution at the lower OD), 
and to select for participants with a relatively recent anti-
body boost across the three sites, only samples with titers 
above a normalized OD (adjusted OD based on a posi-
tive control to correct for inter-plate variations) of 0.5 
were included in the assessment of the avidity index. In 
each plate, hyper-immune sera was included at a dilution 
1:3200 as a positive control.
Data analysis
Participants were stratified into age groups 1–4, 5–15 
and >15  years. Non-parametric comparison of medians 
across groups within a site and across sites for the differ-
ent age groups was performed using the Mann–Whitney 
test. Correlations were performed using the Pearson test. 
Graphs were plotted using Graphpad PRISM version 5 
(Graphpad Software, USA).
Results
Antibody levels in three sites in Uganda
Antibody levels and avidity index (AI) were measured in 
samples from cross sectional surveys conducted at three 
sites in Uganda. Consistent with published data on anti-
body prevalence [31], the proportion of all cross-sectional 
survey samples included in this study (those with a nor-
malized OD ≥ 0.5) increased with transmission intensity 
for AMA-1 (29.1, 43.6, and 67.7% for Walukuba, Kihihi 
and Nagongera, respectively) but not MSP1-19 (14.6, 
34.5, and 27.3% for Walukuba, Kihihi and Nagongera, 
respectively). Amongst included samples, there were no 
significant differences in median antibody levels between 
the three age groups (1–4, 5–15 and >15 years) for either 
MSP1-19 or AMA-1 within each of the three sites. How-
ever, median antibody levels were generally higher in the 
higher transmission sites, with differences more apparent 
for AMA-1 and in older individuals (Table 1).
Relationship between age and antibody avidity
Median avidity index to MSP1-19 at 2 and 5  M GuHCl 
was not significantly different between age groups at all 
three sites. Similarly, median avidity index to AMA-1 
at 2 and 5 M GuHCl showed no difference between age 
groups at all three sites, with the exception of 1–4 versus 
5–15 year olds in Walukuba (73.6 versus 85.1 p = 0.04) 
(Fig. 1).
Relationship between malaria transmission and antibody 
avidity
In contrast to the trends observed in antibody levels, 
the avidity index to MSP1-19 was significantly lower in 
the highest malaria transmission site of Nagongera than 
Kihihi and Walukuba in those over five, at both GuHCl 
concentrations (2 and 5  M) (Fig.  2). There were no sig-
nificant differences in avidity index between sites in chil-
dren under five. Responses to AMA-1 showed a similar 
pattern, with avidity index lower in Nagongera and 
Kihihi than Walukuba in those at least 5 years old at 5 M. 
There was no evidence of correlation between the avid-
ity index to MSP1-19 and AMA-1 at either GuHCl con-
centration (r2 < 0.002, p > 0.5 at 2 and 5 M GuHCl, for 
all three sites). Overall, these findings suggest an inverse 
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Table 1 Antibody responses to MSP1-19 and AMA-1
Statistically significant values (p < 0.05) are in italics
Antigen Age group 
(years)
Site No of partici‑
pants
Median age 
(IQR)
Median OD (IQR) p value
Walukuba vs 
Kihihi
Walukuba vs 
Nagongera
Kihihi vs 
Nagongera
MSP1‑19 1–4 Walukuba 12 3 (2–4) 0.71 (0.60–1.10) 0.08 0.041 0.44
Kihihi 18 3 (1–4) 0.90 (0.70–1.17)
Nagongera 24 1 (1–3) 1.00 (0.73–1.29)
5–15 Walukuba 16 12 (6–13) 0.80 (0.65–1.25) 0.5 0.4 0.8
Kihihi 76 12 (8–13) 0.89 (0.63–1.12)
Nagongera 74 11 (7–13) 0.87 (0.63–1.17)
>15 Walukuba 64 28 (20–40) 0.82 (0.61–1.1) 0.029 0.011 0.4
Kihihi 181 35 (25–48) 0.97 (0.70–1.27)
Nagongera 116 39 (25–55) 1.00 (0.67–1.30)
Total 581
AMA‑1 1–4 Walukuba 18 2 (1–3) 0.86 (0.59–1.10) 0.95 0.18 0.19
Kihihi 21 3 (2–4) 0.79 (0.65–1.11)
Nagongera 63 3 (2–4) 0.92 (0.67–1.2)
5–15 Walukuba 76 9 (6–12) 0.92 (0.67–1.07) 0.005 0.0001 0.6
Kihihi 125 11 (8–13) 1.1 (0.80–1.15)
Nagongera 251 9 (7–12) 1.1 (0.85–1.2)
>15 Walukuba 89 27 (22–32) 0.72 (0.61–0.88) 0.0001 0.0007 0.62
Kihihi 197 34 (22–47) 0.85 (0.68–1.1)
Nagongera 189 34 (22–50) 0.87 (0.65–1.1)
Total 1029
Fig. 1 Avidity index to MSP1‑19 and AMA‑1 across age groups within the three sites, at the two GuHCl concentrations (2 and 5 M). The bars repre‑
sent the median and interquartile range. *p < 0.05
Page 5 of 8Ssewanyana et al. Malar J  (2017) 16:67 
relationship between avidity index and both transmission 
intensity and antibody response to MSP1-19 and AMA-1 
across sites for those above 5 years.
Discussion
This study sought to determine the influence of P. falcipa-
rum exposure on natural acquisition of high avidity anti-
bodies. Avidity was measured to MSP1-19 and AMA-1 
antigens in 581 and 1029 individuals respectively encom-
passing a wide range of ages, from three sites in Uganda 
with transmission intensities ranging from moderate to 
extremely high. These results demonstrated that age had 
a minimal effect on antibody avidity, consistent with pre-
vious studies using similar methods of evaluation, which 
observed slight or inconsistent age-related differences in 
avidity to MSP1-19 and AMA-1 [28, 29]. Importantly, 
despite higher antibody levels, avidity to both antigens 
was significantly lower at the site of highest P. falciparum 
transmission intensity in children ≥5  years and adults. 
These results suggest that affinity maturation to P. falci-
parum antigens may be compromised in the setting of 
very high, perennial exposure to this parasite.
There are at least two potential explanations for this 
study’s main findings, which are neither exhaustive nor 
mutually exclusive: (1) near constant exposure to anti-
gen may impair maturation/persistence of avid antibod-
ies via a number of potential mechanisms; and (2) recent 
infection may result in addition of low avid antibodies to 
the circulation, reducing the proportion which have high 
avidity.
Affinity maturation is acquired through somatic hyper-
mutation during germinal centre reactions, with B cell 
affinity to antigen driving selection that results in the 
production of higher affinity antibodies [37, 38]. Clas-
sical understanding of B cell biology would suggest that 
repeated exposure would be expected to drive several 
rounds of germinal centre reactions, ultimately result-
ing in higher antibody affinities to the pathogen, hence 
higher antibody avidity. In contrast, the results showed 
a lower proportion of avid antibodies in participants liv-
ing in the highest P. falciparum transmission sites, where 
exposure to antigen is most frequent. Animal studies 
suggest that germinal centre development is temporally 
ordered, with short lived plasma cells (SLPC) emerging 
from germinal centres initially, followed by memory B 
cells (MBC) and then, weeks to months later, long lived 
plasma cells (LLPC) that have undergone extensive 
affinity maturation [37, 39]. Disturbance to this process 
resulting from frequent or chronic infections may com-
promise the ultimate development of high affinity MBC 
and LLPC. For example, there is evidence that frequent 
acute malaria interferes with follicular helper T cell dif-
ferentiation and germinal centre architecture in the 
spleen [27, 40–42]. Another hypothesis suggests that P. 
falciparum infection is associated with dysfunction of the 
B cell compartment, including accumulation of atypical 
Fig. 2 Avidity index to MSP1‑19 and AMA‑1 across transmission sites within the three age groups, at the two GuHCl concentrations (2 and 5 M). The 
bars represent the median and interquartile range. *p < 0.05, **p < 0.001, ***p < 0.0001
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memory B cells [43], which could theoretically result in 
the inefficient acquisition and maintenance of antibody 
mediated immunity to malaria [44]. It is also possible that 
frequent exposure to a large number of antigen clones 
may impair affinity maturation to any one of the clones 
and it is likely that the highest transmission site experi-
ence a higher complexity of infection.
In the presence of low antigen levels, affinity matured 
plasma cells that secrete high affinity antibodies should 
be favored over lower affinity plasma cells and circulat-
ing antibodies for survival. These affinity matured plasma 
cells would therefore maintain the blood antibody levels. 
However, in the presence of frequent re-infection, a rela-
tively large antigen load may be more likely to promote 
survival of poorly affinity-matured plasma cells, includ-
ing T cell-independent or extra-follicular B cell reactions. 
Furthermore, acute P. falciparum infection is associated 
with non-specific, polyclonal B cell activation that may 
result in the expansion of low avidity, short lived plasma 
cells [25]. These factors may reduce the proportion but 
not necessarily the titers of high avidity antibodies. In 
contrast, in the absence of recent infection the antibody 
pool is predominantly comprised of high avidity antibod-
ies generated by LLPC after the contraction of the SLPC. 
This may explain why Ugandans in lower transmission 
areas, who on average had a longer duration of time since 
their last infection, had higher proportions of highly avid 
antibodies. Based on this argument, most likely the dif-
ference in avidity index between the low and high trans-
mission sites should have been more pronounced if the 
method allowed to examine samples below with OD <0.5.
The impact of the differences in avidity index observed in 
this study on acquisition of clinical or anti-parasite immu-
nity is not known. While antibody avidity is theoretically 
important in the function of an antibody response [45], 
there are few available empiric data to support the rela-
tionship between avidity and immunity in malaria. Reddy 
et  al. found that individuals with higher antibody avid-
ity to P. falciparum antigens were less likely to experience 
malaria during follow-up [21, 46]. In an RTS,S malaria 
vaccine trial, investigators did not find an association 
between antibody avidity to circumsporozoite protein and 
protection after the last dose of vaccination among chil-
dren, but they did show that the change in avidity between 
second and third vaccination was associated with a 54% 
reduced risk of acquiring malaria [47, 48]. The relation-
ship between avidity measurements and clinical immunity 
is also complex, with numerous factors other than avidity 
at play. High antibody titres may compensate for low avid-
ity; therefore, relatively low avidity in the presence of high 
antibody levels may not have a negative consequence on 
naturally acquired immunity. Clinical data from this study 
show that acquired immunity clearly develops in children 
in Nagongera as well as the other sites, the study site with 
highest P. falciparum transmission, based on reductions in 
the incidence of disease with age [49]. However it is not 
clear whether acquired immunity would develop and be 
maintained more effectively by decreasing the nearly con-
tinuous exposure to blood stage parasites at the site, e.g. 
via chemoprevention or by reducing transmission using 
vector control [50].
The cross-sectional nature of this study limited the abil-
ity to investigate the mechanisms behind the acquisition of 
antibody avidity. Furthermore, this study only investigated 
responses to two of many P. falciparum proteins, and it is 
not yet well established which combinations of responses 
are most relevant for acquisition of immunity. In addi-
tion, while providing an overall estimate of the propor-
tion of the polyclonal antibody pool which is highly avid, 
the ELISA-based methods used in this study were not able 
to measure avidity in participants with OD <0.5 or further 
dissect binding characteristics of the antibodies.
Conclusion
In conclusion, this study showed that avidity to two dif-
ferent P. falciparum antigens was lower in areas of high 
versus low transmission intensity. The mechanisms 
behind these findings as well as their clinical conse-
quences, if any, are not yet clear. A more detailed inves-
tigation, ideally linked to longitudinal investigation of P. 
falciparum exposure as well as a more comprehensive 
analysis of the B cell and antibody response, will be valu-
able in helping to further illuminate these findings.
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